The most prominent example of a fibrosis-related target that was successfully verified in many baseline studies but later used with little or no therapeutic effects in clinical trials with patients with diabetic nephropathy or FSGS is transforming growth factor (TGF)-β (93, 94). Here, TGFB1 is linked to focal segmental glomerulosclerosis.